Payment overview · 2025
General Payments
$1,045.87
65 reported records · 19 companies
Healthcare provider profile · identity verified
Kimberly A Kick, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BATESVILLE, IN · NPI 1992716377
Verified facts
What the public records show
CMS Open Payments records show Kimberly A Kick, M.D. received $1,045.87 in general payments during 2025 across 65 reported records.
PFIZER INC. accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $187.15 | 17.9% | 16 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $176.73 | 16.9% | 9 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $106.72 | 10.2% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $85.30 | 8.2% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $80.71 | 7.7% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $56.25 | 5.4% | 3 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $47.88 | 4.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.54 | 4.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.20 | 4.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.86 | 3.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $32.51 | 3.1% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $24.63 | 2.4% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $19.71 | 1.9% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.93 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.53 | 1.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.45 | 1.8% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $15.73 | 1.5% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.37 | 1.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.67 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,045.87 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $176.73 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $128.05 | 12 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $106.72 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $80.71 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $75.34 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.63 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $59.10 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $59.10 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $56.25 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $52.71 | 4 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $47.88 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.54 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $42.53 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.86 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $32.51 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.28 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.12 | 2 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $24.63 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.53 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 74 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
74 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 536 | 145 |
| Lisinopril | Lisinopril | 413 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 312 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 72 |
| Losartan Potassium | Losartan Potassium | 263 | 62 |
| Gabapentin | Gabapentin | 247 | 47 |
| Simvastatin | Simvastatin | 211 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 210 | 56 |
| Omeprazole | Omeprazole | 204 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 47 |
| Metformin Hcl Er | Metformin Hcl | 143 | 32 |
| Carvedilol | Carvedilol | 139 | 34 |
| Montelukast Sodium | Montelukast Sodium | 134 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 25 |
| Alendronate Sodium | Alendronate Sodium | 127 | 37 |
| Famotidine | Famotidine | 121 | 31 |
| Meloxicam | Meloxicam | 102 | 28 |
| Furosemide | Furosemide | 99 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 98 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 96 | 26 |
| Allopurinol | Allopurinol | 93 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 90 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 21 |
| Atenolol | Atenolol | 88 | 23 |
| Jardiance | Empagliflozin | 87 | 12 |
| Glimepiride | Glimepiride | 86 | 24 |
| Metformin Hcl | Metformin Hcl | 86 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 22 |
| Sertraline Hcl | Sertraline Hcl | 84 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 21 |
| Alprazolam | Alprazolam | 77 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 15 |
| Eliquis | Apixaban | 74 | 13 |
| Tramadol Hcl | Tramadol Hcl | 73 | 19 |
| Spironolactone | Spironolactone | 67 | 16 |
| Prednisone | Prednisone | 64 | 41 |
| Xarelto | Rivaroxaban | 63 | suppressed |
| Potassium Chloride | Potassium Chloride | 61 | 16 |
| Donepezil Hcl | Donepezil Hcl | 57 | 12 |
| Trazodone Hcl | Trazodone Hcl | 55 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 20 |
| Cefdinir | Cefdinir | 54 | 47 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 13 |
| Synthroid | Levothyroxine Sodium | 46 | suppressed |
| Cephalexin | Cephalexin | 44 | 36 |
| Farxiga | Dapagliflozin Propanediol | 44 | suppressed |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Lorazepam | Lorazepam | 39 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 12 |
| Torsemide | Torsemide | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 27 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 25 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 20 |
| Fluconazole | Fluconazole | 23 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 13 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 14 |
| Pregabalin | Pregabalin | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,045.87 · 65 records | PFIZER INC. | ABRYSVO, AREXVY, Azstarys, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FANAPT, FREESTYLE LIBRE 3, INJECTAFER, INSPIRE, Jornay PM, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PENBRAYA, PREVNAR 20, REPATHA, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, TRUMENBA, Veozah, Wegovy, ZAVZPRET, ZEPBOUND, ZURZUVAE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error